Ionis Pharmaceuticals, Inc.: Hypertriglyceridemia trials

The registry lists 12 Hypertriglyceridemia studies with Ionis Pharmaceuticals, Inc. as lead sponsor. 1 are open to participants now and 4 have results posted.

Phase 1 2Phase 2 5Phase 3 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Safety, Tolerability and Efficacy of ION775RecruitingNCT07604974Phase 2
• A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe HypertriglyceridemiaCompletedNCT05355402Phase 2Results posted
• Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)CompletedNCT03385239Phase 2Results posted
• Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver DiseaseCompletedNCT03371355Phase 2Results posted
• The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With HypertriglyceridemiaCompletedNCT02300233Phase 3Results posted
• CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)Active, not recruitingNCT05681351Phase 3
• A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe HypertriglyceridemiaCompletedNCT05610280Phase 3
• A Study of Olezarsen Administered Subcutaneously to Participants With Severe HypertriglyceridemiaCompletedNCT05552326Phase 3
• A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe HypertriglyceridemiaCompletedNCT05079919Phase 3
• Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated TriglyceridesCompletedNCT02900027Phase 1
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial HypercholesterolemiaCompletedNCT02709850Phase 1
• Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in HypertriglyceridemiaCompletedNCT01529424Phase 2